Clinical Research Directory

Inclusion Criteria: * Age between 8.0 to 16.9 years of age. * Capable of giving informed consent, or if appropriate, have an acceptable representative capable of giving consent on the participant's behalf. * Established Crohn's Disease (CD) diagnosis with the site of disease involving at least the terminal ileum or ascending colon. * CD is in clinical remission or with mild stable disease activity (weighted Pediatric Crohn's Disease Activity Index of 0 to 39.5). * Receiving infliximab or adalimumab anti-TNFa monoclonal antibody medication for treatment of CD. * No changes in medical treatment for the previous month and without anticipated changes for the next month. * Ability and willingness to comply with study procedures (e.g., stool collection) for the entire length of the study. Exclusion Criteria: * Allergy to RS or excipients. * Co-existing diagnosis with diabetes mellitus type 1. * Treatment with another investigational drug or intervention throughout the study. * Current illicit drug or alcohol dependence. * Inability or unwillingness of an individual or legal guardian to give written informed consent. * Other conditions requiring immunomodulating or biological medications. * Pregnancy. * Participant's microbiota does not increase butyrate production utilizing any RS from the assembled panel as measured through the RapidAIM ex vivo assay.